[pdf] patents office journal - Irish Patents Office

More documents

Recommendations

Info

811 (05/04/2006) Patents Office Journal (No. 2043) Request for Grant of Supplementary Protection Certificate The name and address of the requestor follow the number allocated to the request. The date in brackets following the name and address is the date of receipt of the request. The Patent number is that under which the product in respect of which a certificate is sought is, allegedly, protected. Market Authorisation references in respect of the product concerned are also shown. 2006009 LES LABORATOIRES SERVIER, 22 rue Garnier, 92200 Neuillysur-Seine, France (1 March 2006) Patent No: 0534859; Benzocyclobutyl- or indanyl-alkyl-amino-alkyl substituted 3-benzazepin-2-ones useful in the treatment of cardiovascular diseases Product: Procoralan - Ivabradine Market Authorisation: Ireland EU/1/05/316/001-014, 25/10/2005 Supplementary Protection Certificates Granted The name and address of the grantee follows the number allocated to the application for grant of a certificate; this number applies also to the granted certificate. The date in brackets following the name and address is the date of grant of the certificate. The number of the basic Patent and the title of the invention are followed by the name of the product for which the certificate is granted. Market authorisation references in respect of the product concerned are also shown, followed by the date of expiry of the certificate. 2002032 E.I. du Pont de Nemours and Company, Wilmington, Delaware 19898, United States of America 10/03/2006 Patent No: 66407; Fungicidal oxazolidinones Product: A formulation comprising a mixture of famoxadone and cymoxanil Market Authorisation: Ireland AP01398, 14/05/2002 Switzerland 5665, 11/12/1997 Certificate Expires on: 10/12/2012 2005002 ELI LILLY AND COMPANY, Lilly Corporate Center, Indianapolis, Indiana 46285, United States of America 08/03/2006 Patent No: 60805; 3-Aryloxy-3-substituted propanamines Product: duloxetine and pharmaceutically acceptable acid addition salts thereof, and in particular, duloxetine hydrochloride Market Authorisation: Ireland EU/1/04/280/001-006, 11/08/2004 Certificate Expires on: 17/12/2012 2005003 MERCK FROSST CANADA & CO., Purdy`s Wharf Tower One, 1959 Upper Water Street, P.O. Box 997, Halifax, Nova Scotia B3J 2X2, Canada 08/03/2006 Patent No: 0863891; (Methylsulfonyl)phenyl-2-(5H)-furanones as cox-2
(No. 2043) Patents Office Journal (05/04/2006) inhibitors Product: Firocoxib optionally in the form of a pharmaceutically acceptable salt. Market Authorisation: Ireland EU/2/04/045/001-004, 13/09/2004 European Union EU/2/04/045/001-004, 13/09/2004 Certificate Expires on: 12/09/2019 2005004 AVENTIS PHARMA DEUTSCHLAND GmbH, Brüningstrasse 50, 65929 Frankfurt am Main, Germany 08/03/2006 Patent No: 0885961; Novel insulin derivatives with rapid onset of action Product: insulin glulisine or a physiologically tolerable salt thereof Market Authorisation: Ireland EU/1/04/285/001-020, 27/09/2004 European Union EU/1/04/285/001-020, 27/09/2004 Certificate Expires on: 26/09/2019 2005006 LES LABORATOIRES SERVIER, 22 rue Garnier, 92200 Neuilly-Sur-Seine, France 08/03/2006 Patent No: 65157; New divalent metal salts of 2-[N,N-di(carboxymethyl)amino]- 3-4- carboxymethylthiophene-5-carboxylic acid, a process for the preparation thereof, and pharmaceutical compositions containing them Product: Protelos-Strontium ranelate Market Authorisation: Ireland EU/1/04/288/001-006, 21/09/2004 European Union EU/1/04/288/001-006, 21/09/2004 Certificate Expires on: 30/08/2015 2005007 PROTEIN DESIGN LABS, INC., 34801 Campus Drive, Fremont, CA 94555, United States of America 16/03/2006 Patent No: 82755; Humanized immunoglobulins and their production and use Product: Bevacizumab, or pharmaceutically acceptable salts thereof. Market Authorisation: Ireland EU/1/04/300/001-02, 12/01/2005 Switzerland 56922, 16/12/2004 Certificate Expires on: 27/12/2014 2005009 SMITHKLINE BEECHAM CORPORATION, One Franklin Plaza, 200 North 16th Street, Philadelphia, PA 19102, United States of America 16/03/2006 Patent No: 0719278; ANDROSTENONE DERIVATIVE Product: Dutasteride, optionally in the form of a pharmaceutically acceptable solvate. Market Authorisation: Ireland 1077/104/01, 17/12/2004 Ireland 1077/105/1, 17/12/2004 Sweden 17871, 19/07/2002 Sweden 17872, 19/07/2002 Certificate Expires on: 18/07/2017 2005010 SCHERING AKTIENGESELLSCHAFT, Berlin and Bergkamen, Germany 16/03/2006 Patent No: 65676; Derivatized DTPA complexes, pharmaceutical agents 812
Page 1 and 2:
PATENTS OFFICE JOURNAL IRISLEABHAR
Page 3 and 4:
(No. 2043) Patents Office Journal (
Page 5 and 6:
Page 7 and 8:
Page 9 and 10:
Page 11 and 12:
Page 13 and 14:
Page 15 and 16:
Page 17 and 18:
Page 19 and 20:
Page 21 and 22:
Page 23 and 24:
Page 25 and 26:
Page 27 and 28:
Page 29 and 30:
Page 31 and 32:
Page 33 and 34:
Page 35 and 36:
Page 37 and 38:
Page 39 and 40:
Page 41 and 42:
Page 43 and 44:
Page 45 and 46:
Page 47 and 48:
Page 49 and 50:
Page 51 and 52:
Page 53 and 54:
Page 55 and 56:
Page 57 and 58:
Page 59 and 60:
Page 61 and 62:
Page 63 and 64:
Page 65 and 66:
Page 67 and 68:
Page 69 and 70:
Page 71 and 72:
Page 73 and 74: (No. 2043) Patents Office Journal (
Page 123: (No. 2043) Patents Office Journal (
Page 127 and 128: 56445 57229 57247 57433 57435 57610
Page 175 and 176:
Page 177 and 178:
Page 179 and 180:
Page 181 and 182:
Page 183 and 184:
Page 185 and 186:
Page 187 and 188:
Page 189 and 190:
Page 191 and 192:
Page 193 and 194:
Page 195 and 196:
Page 197 and 198:
Page 199 and 200:
Page 201 and 202:
Page 203 and 204:
Page 205 and 206:
Page 207 and 208:
Page 209 and 210:
Page 211 and 212:
Page 213 and 214:
show all

[pdf] patents office journal - Irish Patents Office

Create successful ePaper yourself

Delete template?

Save as template?